Collaborative innovation models

While IP ownership is an essential driver of innovation, technological advances are often dependent on shared knowledge, standards, and collaborative innovation. The IP framework must enable both. We must protect truly new, novel, and useful inventions. And we need to recognize that open standards can accelerate the interoperability and expansion of the global infrastructure. Because collaborative innovation is relatively new, the stmcture and processes to accommodate ownership, openness, and access are evolving, and new creative models are emerging. 

Different models of networked innovation and offer a set of guidelines for companies to identify and prepare for the most promising collaborative innovation opportunities. As they emphasize, success also requires us to rethink the very nature of our relationships with innovation partners - what we need to control and what we... 

Baldwin, C. Y. and Von Hippel, E. (2011], "Modeling a Paradigm Shift From Producer Innovation to User and Open Collaborative Innovation," Organization Science, 22 (6], 1399-417... 

The case studies essentially fulfilled three functions in the SubChem project. Firstly, they served as a source of realisation secondly as the background and illustration of hypotheses and type characterisation/modelling of innovation systems and thirdly, for legibility to incorporate our results in narratives about substances . The study proceeded on the basis of document analyses and collaboration with several practice partners in each instance. The cases were selected so that they covered as wide a spectmm of substitution conditions and product types as possible (cf Table 1). In this way the cases covered the following ... 

We then embed this system model into a statistical analysis and 3D interactive multimedia framework (Figure 1). We use statistical methods to capture processes before they go out of control as well as to perform trend analysis, a great opportunity for innovation, and use 3D interactive multimedia and 3D visualization methods over the Web for communication purposes with global innovation team members. The emphasis on collaboration in today s competitive medical drug held requires these virtual environments to streamline team interaction. (Note that the active... 

Depending on the business model(s) chosen, companies need to define their specific innovation headroom . This includes answering questions such as how important are innovations in the segment What do strategic customers need Should companies go for innovation in technology, service offerings, or in the value chain What does that imply for R D capacities and skills How can R D best collaborate with marketing and sales, (potential) customers, and external research institutes What level of external versus internal R D is required ... 

James Desveaux, University of California, Los Angeles You have outlined an impressive degree of innovation and adaptation. A question by another member of the audience has spawned curiosity for me about some organizational design issues, related to the different types of industrial partnerships permitted under the arrangements you described. What you have described sounds a lot like the kind of system that the Microelectronics and Computer Technology Corporation in Austin put in place a number of years ago. In fact, what you have discussed even bears some resemblance to partnership innovations recently made by the partners of the Semiconductor Research Corporation. Where did the ideas come from for the collaborative iimovations that you outlined Did you actively scan other models To what extent are these models rephcable ... 

The result of this exemplary partial process is the C3 model for the delegation of the computational process anlysis to an externel partner in the scenario. Complementary to these interdisciplinary work processes also collaboration aspects within the plastics engineering domain were examined. Therefore the tasks of process analysis by integrated ID and 3D simulation as well as the interactive exploration of huge simulation result data in a virtual 3D space were improved by innovative tools and methods driven by real world scenarios. 

Academia has seen a major shift toward the production of clinical candidates via translational research aided by universities themselves, government and foundation funding, and, in some cases, even outsourcing-for-equity use of CROs. The biotech industry now supplies an increasing number of clinical candidates to pharma via collaboration or acquisition, the value of such deals having gone up tremendously in recent years as pharma looks farther abroad for potential new blockbusters. Genentech, the California model of biotech success, has now become a different sort of model the financial stability afforded by big pharma (Roche) majority ownership combined with its relative autonomy has resulted in innovative new therapies as well as profits that would not have been attainable by either party alone. 

Testing Consortium and the Innovative Medicine Initiative, which have fueled the pace of research progress in predictive toxicology. These precompetitive collaborations represent ideal forums to share ideas and experience but also to test in an efficient and systematic way new methods for toxicity prediction. These collaborative efforts will undeniably accelerate the development of novel models or biomarkers that will ultimately benefit patients and support animal welfare efforts. Companies and scientists should be encouraged to be actively involved in those forums. 

---